A biodegradable drug delivery system for the treatment of postoperative inflammation
Details
Serval ID
serval:BIB_1FF2F31A6AD1
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A biodegradable drug delivery system for the treatment of postoperative inflammation
Journal
International Journal of Pharmaceutics
ISSN
0378-5173 (Print)
Publication state
Published
Issued date
2008
Volume
352
Number
1-2
Pages
240-247
Language
english
Notes
DA - 20080226
LA - eng
RN - 0 (Anti-Inflammatory Agents)
RN - 0 (Delayed-Action Preparations)
RN - 0 (Drug Carriers)
RN - 0 (polylactic acid-polyglycolic acid copolymer)
RN - 26009-03-0 (Polyglycolic Acid)
RN - 50-21-5 (Lactic Acid)
RN - 76-25-5 (Triamcinolone Acetonide)
SB - IM ; Research Support, Non-U.S. Gov't
LA - eng
RN - 0 (Anti-Inflammatory Agents)
RN - 0 (Delayed-Action Preparations)
RN - 0 (Drug Carriers)
RN - 0 (polylactic acid-polyglycolic acid copolymer)
RN - 26009-03-0 (Polyglycolic Acid)
RN - 50-21-5 (Lactic Acid)
RN - 76-25-5 (Triamcinolone Acetonide)
SB - IM ; Research Support, Non-U.S. Gov't
Abstract
Cataract surgery is often performed in patients suffering from associated pathologies. Our goal is to develop a biodegradable drug delivery system (DDS) combined with the artificial intraocular lens (IOL). DDS were manufactured using poly(D,L-lactide-co-glycolide), or PLGA, and were loaded with triamcinolone acetonide (TA). The loading capacity was approximately 1050 microg of TA per DDS. The higher the molecular weight of PLGA (34,000, 48,000 and 80,000Da), the slower was the release of TA in vitro. Cataract surgery was performed on the right eye of rabbits. IOL was inserted with (i) no DDS, (ii) unloaded DDS PLGA48000, (iii) one loaded DDS PLGA48000, (iv) two loaded DDS. The number of inflammatory cells and the protein concentration were measured in the aqueous humor (AH). Unloaded DDS showed good ocular biocompatibility. One DDS PLGA48000 loaded with TA significantly reduced postoperative ocular inflammation. Two loaded DDS PLGA48000 was even more effective in inhibiting such inflammation. On long-term observation (days 63 and 84), reduction of inflammation could be obtained by insertion of one DDS PLGA48000 and a second DDS PLGA80000. Therefore, our "all in one" system is very promising since it could replace oral treatment and reduce the number of intraocular injections
Keywords
adverse effects , Animals , Anti-Inflammatory Agents , Aqueous Humor , Cataract , Cataract Extraction , chemistry , Chemistry,Pharmaceutical , Delayed-Action Preparations , Drug Carriers , Drug Compounding , etiology , Eye , France , Inflammation , Lactic Acid , Lens Implantation,Intraocular , Lenses,Intraocular , metabolism , Models,Animal , Molecular Weight , pathology , Patients , pharmacokinetics , pharmacology , Polyglycolic Acid , prevention & control , Prosthesis Design , Rabbits , Solubility , surgery , Switzerland , Technology,Pharmaceutical , Triamcinolone Acetonide
Pubmed
Web of science
Create date
29/01/2009 22:13
Last modification date
20/08/2019 12:55